Author

T. Graeber

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Approach:biophysical modeling· 1

Frequent Co-Authors

J. Freeland· 2 shared A. Ridley· 1 shared C. M. Storey· 1 shared C. Yuen· 1 shared C.-C. Chen· 1 shared D. Abou· 1 shared D. Cheng· 1 shared D. L. Thorek· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Freeland

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

PGC-1a drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity

G. Varuzhanyan, C.-C. Chen, J. Freeland, T. He, W. Tran, K. Song, L. Wang, D. Cheng, S. Xu, G. A. Dibernardo, F. N. Esedebe, V. Bhatia, M. Han, E. R. Abt, J. W. Park, , O. N. Witte

bioRxiv · Apr 9, 2024Cancer Biology

Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

C. M. Storey, M. Altai, K. M. Lueckerath, W. Zedan, H. Zhu, M. Trajkovic-Arsic, J. E. Park, N. Peekhaus, J. Siveke, H. Lilljebjorn, D. Abou, H. L. Marks, E. Ulmert, H. Lilja, A. Ridley, , D. Ulmert

This paper develops a radio-theranostic approach targeting LRRC15 to image and treat cancer, showing tumor reduction and reversal of immunotherapy resistance.

bioRxiv · Jan 30, 2024 · PreprintPharmacology & Toxicology

Genetic Screen in a Pre-Clinical Model of High-Grade Complex Karyotype Sarcoma Characterizes Drivers of Distinct Sarcoma Subtypes and Identifies New Therapeutic Vulnerabilities

M. A. Munoz, J. Freeland, E. O'Donnell, J. Langerman, J. Bergonio, J. Surarez-Navarro, M. Darrow, S. Thorpe, R. Randall, K. L. Carraway, O. Witte, T. Graeber, J. Carr-Ascher

This paper develops a pre-clinical model of high-grade complex karyotype sarcomas to identify subtype-specific drivers and therapeutic targets through genetic screening and transcriptomic analysis.

bioRxiv · Jun 13, 2022 · PreprintCancer Biology

In vivo CRISPRi screen reveals the differential requirement for mitochondrial respiratory chain function between in vivo and in vitro tumor growth

H. Nakaoka, N. Bennett, R. Okimoto, D. Laurent, Y. Sei, T. Bivona, J. ten Hoeve, T. Graeber, K. Nakamura, J. Nakamura

The paper uses CRISPRi to show that mitochondrial respiratory chain genes are critical for in vivo tumor growth but not for metastasis in lung cancer xenografts.

bioRxiv · Oct 3, 2021 · PreprintCancer Biology